Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico(2013)
Abstract
Purpose To assess the impact in pathological complete response (pCR) and outcome of two dose-dense neoadjuvant chemotherapy (DDNC) regimens among different histological subtypes determined by hormonal receptor (HR) and HER2 status in breast cancer patients. Methods A total of 127 breast cancer patients were treated with DDNC in two prospective studies. A: adriamycin 40 mg/m 2 on day (d) 1 plus paclitaxel 150 mg/m 2 and gemcitabine 2,000 mg/m 2 on d2 for six cycles ( n = 54). B: epirubicin 90 mg/m 2 , cyclophosphamide 600 mg/m 2 on d1 for three cycles, followed by paclitaxel 150 mg/m 2 and gemcitabine 2,500 mg/m 2 on d1 ± trastuzumab according to HER2 status ( n = 73). Histological subtypes of breast cancer were 49 % HR+/HER2−, 17.5 % HR+/HER2+, 13.5 % HR−/HER2+ and 20 % HR−/HER2−. Results pCR (absence of invasive cells in breast and lymph node) was achieved in 35 patients (28 %). The pCR rate was significantly different between histological subtypes: HR+/HER2− (9 %), HR+/HER2+ (23 %), HR−/HER2+ (50 %), HR−/HER2− (56 %) ( p < 0.001). The median follow-up was 81 months (r: 15–150 months). HR−/HER2− tumor subtype had a significantly worse DFS compared to HR+/HER2− ( p = 0.02), RH+/HER2+ ( p = 0.04) and HR−/HER2+ tumor subtypes ( p = 0.02). HR−/HER2− tumor subtype had a significantly shorter OS compared to HR+/HER2− ( p = 0.007), RH+/HER2+ ( p = 0.05), and HR−/HER2+ ( p = 0.03) tumor subtypes. However, no significant difference was observed in DFS and OS among HR−/HER2− tumors that achieved a pCR. Conclusions HR−/HER2− and HR−/HER2+ subtypes had a high pCR rate to DDNC. HR−/HER2− tumors had a worse outcome compared to other tumor subtypes but no significant difference was observed among HR−/HER2− tumors that achieved a pCR.
MoreTranslated text
Key words
Neoadjuvant chemotherapy, Pathological complete response, Histological subtypes, Outcome, Breast cancer, Dose-dense
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined